JP2018516256A - 治療用ワクチンとしての使用のためのナノ粒子 - Google Patents

治療用ワクチンとしての使用のためのナノ粒子 Download PDF

Info

Publication number
JP2018516256A
JP2018516256A JP2017561738A JP2017561738A JP2018516256A JP 2018516256 A JP2018516256 A JP 2018516256A JP 2017561738 A JP2017561738 A JP 2017561738A JP 2017561738 A JP2017561738 A JP 2017561738A JP 2018516256 A JP2018516256 A JP 2018516256A
Authority
JP
Japan
Prior art keywords
cancer
nanoparticles
subject
nanoparticle
radiation therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017561738A
Other languages
English (en)
Japanese (ja)
Inventor
マリル，ジュリー
ポティエ，アニエス
レヴィ，ローラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobiotix SA
Original Assignee
Nanobiotix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix SA filed Critical Nanobiotix SA
Publication of JP2018516256A publication Critical patent/JP2018516256A/ja
Priority to JP2023051686A priority Critical patent/JP7570134B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017561738A 2015-05-28 2016-05-27 治療用ワクチンとしての使用のためのナノ粒子 Pending JP2018516256A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023051686A JP7570134B2 (ja) 2015-05-28 2023-03-28 治療用ワクチンとしての使用のためのナノ粒子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305810.2 2015-05-28
EP15305810 2015-05-28
PCT/EP2016/061989 WO2016189125A1 (en) 2015-05-28 2016-05-27 Nanoparticles for use as a therapeutic vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023051686A Division JP7570134B2 (ja) 2015-05-28 2023-03-28 治療用ワクチンとしての使用のためのナノ粒子

Publications (1)

Publication Number Publication Date
JP2018516256A true JP2018516256A (ja) 2018-06-21

Family

ID=53298299

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017561738A Pending JP2018516256A (ja) 2015-05-28 2016-05-27 治療用ワクチンとしての使用のためのナノ粒子
JP2023051686A Active JP7570134B2 (ja) 2015-05-28 2023-03-28 治療用ワクチンとしての使用のためのナノ粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023051686A Active JP7570134B2 (ja) 2015-05-28 2023-03-28 治療用ワクチンとしての使用のためのナノ粒子

Country Status (19)

Country Link
US (2) US11096962B2 (enExample)
EP (1) EP3302419A1 (enExample)
JP (2) JP2018516256A (enExample)
KR (1) KR102727195B1 (enExample)
CN (2) CN118286421A (enExample)
AR (1) AR104806A1 (enExample)
AU (2) AU2016269146B2 (enExample)
BR (1) BR112017025553A2 (enExample)
CA (1) CA2987331A1 (enExample)
EA (1) EA201792560A1 (enExample)
HK (1) HK1246160A1 (enExample)
IL (1) IL255853B (enExample)
MA (1) MA43100A (enExample)
MX (2) MX2017015424A (enExample)
NZ (1) NZ738527A (enExample)
TW (2) TWI873079B (enExample)
UA (1) UA124572C2 (enExample)
WO (1) WO2016189125A1 (enExample)
ZA (1) ZA201708686B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022505408A (ja) * 2018-10-19 2022-01-14 ユニバーシティ オブ ロチェスター 進行膵癌の放射線処置と組み合わせた免疫調節薬
JP2023549698A (ja) * 2020-11-05 2023-11-29 ナノビオティックス がんの治療のためのナノ粒子の組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CN120417926A (zh) 2022-12-12 2025-08-01 纳米生物技术公司 用作放射增敏剂或用于可视化生物组织的新型金属氧化物纳米颗粒及其组合物
CN116370625B (zh) * 2023-03-14 2024-10-11 浙江大学 一种哑铃状的金-氧化铈纳米材料的制备方法及其产品和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524866A (ja) * 2008-06-05 2011-09-08 ナノビオティックス 無機ナノ粒子、その調製および使用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
CA2137145A1 (en) 1992-06-08 1993-12-23 Mark S. Chagnon Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
WO1994002068A1 (en) 1992-07-21 1994-02-03 The General Hospital Corporation System of drug delivery to the lymphatic tissues
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
JP2930421B2 (ja) 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
WO1998040049A2 (de) 1997-03-07 1998-09-17 Max-Delbrück-Centrum für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6645464B1 (en) 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
EP2343047B2 (en) 2000-02-08 2021-03-17 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
ES2258527T3 (es) 2000-05-05 2006-09-01 Bayer Technology Services Gmbh Nanoparticulas impurificadas como biomarcadores.
WO2002029410A2 (en) 2000-10-06 2002-04-11 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
BR0115127A (pt) 2000-11-20 2004-02-17 Oncolytics Biotech Inc Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6756063B2 (en) 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
AU2002351240A1 (en) 2002-03-08 2003-09-22 James Hainfeld Gold nanoparticles used for x-rays imaging
US20030191458A1 (en) 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
CA2513759C (en) 2003-01-24 2014-05-13 The Research Foundation Of State University Of New York Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP2007511503A (ja) 2003-11-17 2007-05-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 医療画像化技術用の造影剤及びその使用
AU2004308756B2 (en) 2003-12-22 2010-06-24 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
US20080193372A1 (en) 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
JP4895151B2 (ja) 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (en) 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
JP5082446B2 (ja) 2004-11-10 2012-11-28 コニカミノルタエムジー株式会社 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
FR2884149B1 (fr) 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007052267A2 (en) 2005-11-01 2007-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US20070098641A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
RU2009104312A (ru) 2006-07-10 2010-08-20 Конинклейке Филипс Электроникс Н.В. (Nl) Наночастицы типа "ядро-оболочка" для терапии и диагностических целей
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
IL181126A0 (en) 2006-11-01 2007-07-04 S B Biotechnologies Ltd Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1920784A1 (en) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
EA201070296A1 (ru) 2007-08-21 2010-08-30 Алза Корпорейшн Липосомные композиции для введения in vivo соединений бороновой кислоты
JP2009067613A (ja) 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
DE102008000852A1 (de) 2008-03-27 2009-10-01 Bosch Mahle Turbo Systems Gmbh & Co. Kg Abgasturbolader für ein Kraftfahrzeug
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
US8395131B2 (en) 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
EP2305310A1 (en) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EP3960215B1 (en) 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
HRP20160609T1 (hr) 2010-03-26 2016-09-23 Abraxis Bioscience, Llc Postupci liječenja hepatocelularnog karcinoma
WO2011133228A2 (en) 2010-04-23 2011-10-27 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012009406A2 (en) 2010-07-13 2012-01-19 University Of Utah Research Foundation Gold particles and methods of making and using the same in cancer treatment
EP2624874A4 (en) 2010-10-08 2014-04-02 Univ Texas Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
JP2014516960A (ja) * 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
US10064960B2 (en) 2011-11-25 2018-09-04 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
MX362089B (es) 2011-12-16 2019-01-07 Nanobiotix Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
IN2014MN02089A (enExample) 2012-03-20 2015-09-11 Einstein Coll Med
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
CA2897362C (en) 2013-01-25 2023-02-14 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US20140219926A1 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy
BR112015029853A2 (pt) 2013-05-30 2017-07-25 Nanobiotix uso de uma composição farmacêutica
MA38709A1 (fr) 2013-06-20 2018-05-31 Nanobiotix Compositions et procédés pour une utilisation en diagnostic médical
AU2014283232B2 (en) 2013-06-20 2019-03-28 Nanobiotix Compositions and methods for use in oncology
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
CA2968473A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
JP6789960B2 (ja) 2014-11-25 2020-11-25 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製及び使用
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524866A (ja) * 2008-06-05 2011-09-08 ナノビオティックス 無機ナノ粒子、その調製および使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CRITTENDEN M ET AL.: "Current clinical trials testing combinations of immunotherapy and radiation", SEMINARS IN RADIATION ONCOLOGY, vol. 25, no. 1, JPN6020020722, January 2015 (2015-01-01), pages 54 - 64, ISSN: 0004765600 *
GOLDEN, E. B., APETOH, L.: "Radiotherapy and immunogenic cell death", SEMINARS IN RADIATION ONCOLOGY, vol. 25, no. 1, JPN6021021426, January 2015 (2015-01-01), pages 11 - 17, ISSN: 0005081492 *
GRAF MR ET AL.: "Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with c", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 51, no. 4, JPN6020020724, 2002, pages 179 - 189, ISSN: 0004765596 *
KEPP O ET AL.: "Consensus guidelines for the detection of immunogenic cell death", ONCOIMMUNOLOGY, vol. 3, no. 9, JPN6020020727, 2014, pages 955691, ISSN: 0004765599 *
MAGGIORELLA, L. ET AL.: "Nanoscale radiotherapy with hafnium oxide nanoparticles", FUTURE ONCOLOGY, vol. 8, no. 9, JPN6020020721, 2012, pages 1167 - 1181, ISSN: 0005081490 *
SCHAUE, D. ET AL.: "Maximizing tumor immunity with fractionated radiation", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 83, no. 4, JPN6022050164, 2012, pages 1306 - 1310, ISSN: 0004930919 *
VATNER, R. E. ET AL.: "Combinations of immunotherapy and radiation in cancer therapy", FRONTIERS IN ONCOLOGY, vol. 4, JPN6021021423, 2014, pages 325, ISSN: 0005081491 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022505408A (ja) * 2018-10-19 2022-01-14 ユニバーシティ オブ ロチェスター 進行膵癌の放射線処置と組み合わせた免疫調節薬
JP7450944B2 (ja) 2018-10-19 2024-03-18 ユニバーシティ オブ ロチェスター 進行膵癌の放射線処置と組み合わせた免疫調節薬
US12186590B2 (en) 2018-10-19 2025-01-07 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
JP2023549698A (ja) * 2020-11-05 2023-11-29 ナノビオティックス がんの治療のためのナノ粒子の組成物

Also Published As

Publication number Publication date
AU2021202582A1 (en) 2021-05-27
NZ738527A (en) 2022-07-01
CN118286421A (zh) 2024-07-05
ZA201708686B (en) 2025-03-26
US20210353670A1 (en) 2021-11-18
CA2987331A1 (en) 2016-12-01
NZ776598A (en) 2024-10-25
UA124572C2 (uk) 2021-10-13
BR112017025553A2 (pt) 2018-08-07
US20180147237A1 (en) 2018-05-31
TW202417036A (zh) 2024-05-01
CN107708668A (zh) 2018-02-16
MA43100A (fr) 2018-09-05
AU2016269146B2 (en) 2021-01-28
EA201792560A1 (ru) 2018-06-29
US11096962B2 (en) 2021-08-24
TWI873079B (zh) 2025-02-21
JP2023082080A (ja) 2023-06-13
HK1246160A1 (zh) 2018-09-07
AR104806A1 (es) 2017-08-16
MX2023007706A (es) 2023-07-10
TW201705977A (zh) 2017-02-16
KR20180012823A (ko) 2018-02-06
EP3302419A1 (en) 2018-04-11
IL255853B (en) 2020-08-31
IL255853A (en) 2018-01-31
AU2021202582B2 (en) 2022-12-15
JP7570134B2 (ja) 2024-10-21
WO2016189125A1 (en) 2016-12-01
AU2016269146A1 (en) 2018-01-18
KR102727195B1 (ko) 2024-11-06
MX2017015424A (es) 2018-03-01

Similar Documents

Publication Publication Date Title
JP7570134B2 (ja) 治療用ワクチンとしての使用のためのナノ粒子
Zhao et al. In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy
Xiao et al. Icaritin-loaded PLGA nanoparticles activate immunogenic cell death and facilitate tumor recruitment in mice with gastric cancer
Li et al. Nanomaterials enhance the immunomodulatory effect of molecular targeted therapy
Carney et al. Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases
Chen et al. A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma
Yao et al. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer
Mu et al. A chemoimmunotherapy nanogel enables efficient delivery of interleukin‐2 and induction of immunogenic cell death for effective cancer therapy
CN108379562B (zh) 一种聚合物纳米佐剂及其制备方法和用途
Zhang et al. ATP-responsive and functionalized framework nucleic acid for synergistic radio-immunotherapy
Zhang et al. A syringeable immunotherapeutic hydrogel enhances T cell immunity via in-situ activation of STING pathway for advanced breast cancer postoperative therapy
KR20230038659A (ko) 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합
Chu et al. Virus-mimicking nanoparticles potentiate in-situ cancer vaccines by reversing intratumoral DCs via stimulating cytosolic nucleic acid sensors
Xu et al. The enhancing effect of DNA tetrahedron-based lactoferrin as an assembled adjuvant in immunotherapy
JP2023549698A (ja) がんの治療のためのナノ粒子の組成物
EA040587B1 (ru) Способ лечения злокачественных новообразований
Gupta et al. Delivery strategies of immunotherapies in the treatment of colorectal cancer
Schunke Adjuvant-loaded protein-based nanocapsules induce effective anti-cancer immunity
Moorthy et al. Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer
HK40087511A (zh) 纳米粒子、电离辐射及其创新治疗组合
CN116650663A (zh) 一种适配体-膜融合脂质体纳米药物及其制备方法和应用
CN116891828A (zh) 新型的免疫刺激分子及改造的外泌体及其制备方法和应用
CN120381534A (zh) 具备抗原捕获能力的表面载药多功能工程益生菌、制备方法及应用
CN119405804A (zh) 一种无需抗原的生物可降解纳米制剂及其应用
CN113274352A (zh) 一种纳米制剂及其制备方法与应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230328

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230328

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230411

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230515

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230616